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Background: The illegal administration of hormones, steroids, β-agonists and other anabolic agents to productive
livestock in the European Union continues, despite the long-term ban on their use and despite the measures
provided under the directives to monitor certain substances and residues thereof in the interest of protecting
consumer health and animal wellbeing. Often administered in low doses in the form of a drug cocktail, these
compounds escape detection by common analytical techniques. The aim of this study was to determine whether
low-dose dexamethasone administration (0.4 mg orally per day, for 20 days) in white-meat calves produced
variations in blood coagulation, as measured by thromboelastometry. A second aim was to determine whether
such variations could be valid in detecting illicit low-dose dexamethasone treatment.
Results: The study population was 42 Friesian calves kept under controlled conditions until 6 months of age. The
calves were subdivided into 2 groups: a control group (group A, n = 28) and a group treated with dexamethasone
(group B, n = 14) for 20 days beginning at 5 months of age. When compared against the age-matched control
group, the dexamethasone-treated calves showed a significant increase in alpha angle, maximum clot firmness and
a significant decrease in clot formation time on all thromboelastometric profiles (P < 0.05). The clotting time was
significantly decreased on the in-TEMW profile but increased on the ex-TEMW and fib-TEMW profiles (P <0.05). The
Receiver Operating Characteristic curves, plotted for the Maximum Clot Elasticity (MCE), had a cut-off
value ≥488.23 mm for in-TEMW MCE [Se 85.7%, (95% CI 57.2-98.2); Sp 100% 96.43% (95% CI 81.7-99.9] and a cut-off
value ≥63.94 mm for fib-TEMW MCE [Se 92.8 (95% CI 66.1-99.8); Sp 89.3% (95% CI 71.8-97.7)]. In order to increase
the sensitivity of the test two parameters (in-TEMW and fib-TEMW MCE) were used as two parallel tests;
subsequently, the sensitivity rose to a point value of 99% (95% CI 85.4-99.9).
Conclusions: Thromboelastometry identified a state of hypercoagulability in the dexamethasone-treated subjects.
Furthemore, the results of this preliminary study suggest that TEM may be useful in the detection of illicit low-dose
dexamethasone treatment.
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Synthetic corticosteroids and their residues constitute a
potential risk for human health, as they can mimic, block
or interfere with hormone actions [1]. For therapeutic
indications only, the use of some glucocorticosteroids is
allowed and therefore maximum residue limits have been
established for bovine edible tissues (0.75 μg per kg in
kidney and muscle, and 2 μg per kg in liver) and milk
(0.3 μg per kg).a
The illegal administration of hormones, steroids, β-
agonists and other anabolic agents to productive live-
stock in the European Union continues, despite the
long-term ban (Council Directives 96/22 EC and 96/23
EC) on their use and despite the measures provided
under the directives to monitor certain substances and
residues thereof in the interest of protecting consumer
health and animal wellbeing. Numbering among the
most widely used illicit anabolic agents are β-agonists
(clenbuterol and ractopamine), sex hormones (estradiol,
testosterone and nortestosterone) and corticosteroids
(dexamethasone and betamethasone) [2,3]. Often admin-
istered in low doses in the form of a drug cocktail, these
compounds escape detection by common analytical
techniques such as chromatograph/mass spectrometry
and liquid chromatography tandem mass spectrometry
which provide unreliable results. For years the scientific
community has worked to identify possible markers for
illicit drug treatments and to find which markers would
be useful in additions to traditional detection methods.
Screening methods to investigate either the temporary
or the permanent effects of the use of such drugs could
be useful and some of them have already been put in
place [4-7]. On the contrary there are still some effects
that have to be further investigated, such those on hor-
monal, hematological and biochemical parameters.
In vitro and in vivo studies on the effects of cortico-
steroids on blood coagulation in humans have identi-
fied increased clotting factors (e.g., factor VIII or von
Willebrand factor) and decreased fibrinolysis [8-11]
which could lead to hypercoagulability. Furthermore,
thrombotic and thromboembolic events have been
reported as a complication of hyperadrenocorticism in
both human and canine patients [9,12,13]. In Cushing’s
syndrome, or in exogenous steroid administration, al-
terations of the hemostatic system have been described
in human beings and in dogs [9-11,14-16].
Presently, there is no gold standard for the diagnosis
of hypercoagulability; however, one of the most reliable
methods for coagulation monitoring and testing is the
viscoelastic technique applied in both human medicine
[17-19] and veterinary medicine [20-26]. Invented by
Hartet in 1948, the technique involves whole blood as-
sessment that takes into account the plasma and the cel-
lular components of hemostasis. Standard coagulationprofiles end as soon as fibrin strands appear, whereas
viscoelastic technique continues through the following
steps of clot development [27]. Moreover, it allows the
assessment of the hypercoagulable state, which is very
difficult to evaluate with routinely used coagulation
assays.
Three instruments are currently used in medicine:
Sonoclot; Thromboelastography (TEG); and Thrombo-
elastometry (TEM).
The aim of this preliminary study was to determine
whether TEM could detect variations in coagulation
induced by low-dose dexamethasone administration
(0.4 mg orally per day, for 20 days) in white-meat calves.
A second aim was to determine whether such changes
as measured by TEM could identify illicit dexametha-
sone treatment.
Methods
This study is an integral part of a research project ap-
proved by the Ministry of Health and the Bioethics
Commission. The study was conducted according to ani-
mal welfare considerations and regulations, and the
protocol was approved by the Italian Ministry of Health
(RF-IZP-2006-364645).
Animals
A total of 122 male Friesian veal calves (age range,
15–35 days) were bought from local breeders, ran-
domly divided into two groups matched for body
weight and age, and farmed in two boxes under the
same conditions for 6 months [6]. Each box had its
own crib, multiple drinking troughs, and a dedicated
automated milk feeder system. To protect the animals
against infections, all were vaccinated against infectious
bovine rhinotracheitis, parainfluenza-3 virus, bovine re-
spiratory syncytial virus and bovine viral diarrhea virus.
Clinical controls were carried out daily by a veterinarian,
and the animals entering the study had received no med-
ical treatment during their lifespan. During the sixth
month, 81 animals received dexamethasone 21-(disodium
phosphate) (0.4 mg per day) orally for 20 days and the
remaining 41 animals were used as controls. Further de-
tails on the trial design can be read in Bozzetta et al., 2011.
Among the largest population that entered in the trial,
two subgroups were randomly extracted: a control group
(group A, n = 28) and a dexamethasone-treated group
(group B, n = 14). These two subgroups entered this
study. The drug was administered orally for 20 days
(0.4 mg per day) beginning at 5 months of age. Upon
completion of treatment (day 20), blood from both
groups was drawn for sampling via jugular venipuncture
using minimum stasis and avoiding vessel damage.
When samples were difficult to obtain, they were
discarded and blood collection was repeated from the
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21G needles and divided into 2 test tubes, one containing
Na-citrate (Venosafe 3.8%, Terumo; for a final ratio of 9:1)
for analysis of hemostasis, and the other containing
K3-EDTA for Complete Blood Count (CBC).
Hemostasis
Coagulation was analyzed via rotational thromboelas-
tometry (ROTEMW, TEM Innovation GmbH). TEM was
evaluated directly in the field within 30 minutes of blood
collection, as directed by the manufacturer’s instruc-
tions, and the analyses were run for 30 minutes. Three
profiles (in-TEMW, ex-TEMW, and fib-TEMW) were
differentiated with the addition of specific reagents: the
in-TEMW, containing ellagic acid, is used to study the in-
trinsic pathway; the ex-TEMW reagent, containing tissue
factor (thromboplastin, factor III), is used to study ex-
trinsic coagulation; and fib-TEMW, containing cytochala-
sin D, an inhibitor of platelet function, allows qualitative
evaluation (fibrin polymerization) of fibrinogen.
Thromboelastometry provides a reaction curve (Figure 1)
representing various different physiological events medi-
ated by the interaction of platelets, coagulation factors,
fibrinogen and the fibrinolysis system. The numerical pa-
rameters are derived from a detailed mathematical analysis
of the reaction curve. The first parameter obtained is the
clotting time ([CT], s), which is mainly affected by the
concentration of plasma coagulation factors and coagu-
lation inhibitors (e.g., antithrombin or drugs) [27]. This
parameter is related, but not identical, to traditional co-
agulation tests (prothrombin time and activated partial
thromboplastin time). The clot formation time ([CFT],
s) and α angle (α, degree), which is the slope of the tan-
gent to the curve, express the velocity of clot formation
and are affected predominantly by platelet number and
function, as well as by fibrinogen activity. Maximum
clot firmness ([MCF], mm) is determined by bothFigure 1 Example of a normal thromboelastogram (ex-TEMW
profile). CT: Clotting time; CFT: Clot formation time; MCF: Maximum
clot firmness.platelet and fibrin formation in the presence of factor
XIII [27]. Moreover, as it seems that MCF does not re-
flect the actual physical properties of cloth strength
according to Hooke’s law, a new parameter was calcu-
lated by transforming MCF: maximum clot elasticity
(MCE), given by (MCFx100)/(100-MCF), as described
in Lang et al., 2009 [28].
CBC tests
CBC were performed (ADVIAW 120 Hematology System,
Siemens Diagnostics) simultaneously with cytological ana-
lysis of a fresh blood smear.
Statistical analysis
The thromboelastometry parameters were expressed as
the median, minimum and maximum value. Reference
values obtained from the control group were expressed
as 5th – 95th percentile. The differences between the
control and the treatment groups were evaluated using
the Wilcoxon rank sum test. A value of P < 0.05 was
considered significant. To identify a cut-off value that
could correctly separate the maximum number of
treated animals from the controls, a Receiver Operating
Characteristic (ROC) curve was plotted for the MCE
parameters.
On the basis of the results given by ROC curves, the
best discriminatory value was used to calculate the valid-
ity of the MCE parameters in correctly identifying
treated and control animals.
Furthermore the results of the assessment of the pa-
rameters (i.e. sensitivity of MCE) were used to evaluate
the sample size useful to detect the absence of illicit
treatment in a bovine farm. A sample size for freedom
from treatment was calculated by assuming the low band
of the Confidential Interval (CI) of the sensitivity (Se) of
the MCE parameters (i.e. worst case scenario), a finite
population (100–500 animals), a confidence level of
95%, and a design prevalence of 33%. To improve the
diagnostic sensitivity, two parameters (fib-TEM MCE
and in-TEM MCE) were joined and used as two parallel
tests [29].
Statistical analysis was performed using Software Stata
11 MP and sample size was calculated by using the
EpiTools1, a web-based suite of epidemiological. b
Results
Table 1 reports the TEM results for group A and group B
and the statistical comparison between the two groups.
When compared against the age-matched control group,
the treatment group showed a significant increase in alpha
angle and MCF, and a significant decrease in CFT on all
profiles. The CT was significantly decreased on the in-
TEMW profile but increased on the ex-TEMW and fib-
TEMW profiles. As representative of the difference between
Table 1 Results of thromboelastometry in control calves (group A) and dexamethasone-treated calves (group B)
CT sec CFT sec MCF mm ALPHA degree
Group A Group B Group A Group B Group A Group B Group A Group B
in-TEM 257 221.5* 59.5 36.5* 78.5 86* 78 83*
172.8-360.7 169.6-275 42.4-79.3 29-46.4 74.4-82.7 83-88.7 75-82 80.7-84
ex-TEM 74 84* 94 57.5* 78.5 86* 75 78*
58.8-88.2 69.9-105.7 67.1-118.7 50-79.8 72.4-84.7 78.3-89.4 70-77.7 75.7-80
fib-TEM 74.5 82.5* 104 59.5* 31.5 47.5* 76.5 78*
61.1-83 71.2-97.8 68.1-322.1 47.3-83.8 25.4-42 41-58 71.7-79 75-80.3
* Statistically significant differences between the control and the treated group (P < 0.05).
(Values are expressed as median and 5th-95th percentile).
CT: Clotting Time; CFT: Clot Formation Time; MCF: Maximum Clot Firmness.
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TEMWMCE are shown in Figure 2.
The ROC curves indicating the best discriminatory
power between the treated and control groups had a cut-
off value ≥488.23 for in-TEMW MCE [Se 85.7%, (95%
CI 57.2-98.2); Sp 96.43% (95% CI 81.7-99.9] (Figure 3) and
a cut-off value ≥ 63.94 for fib-TEMW MCE [Se 92.8 (95%
CI 66.1-99.8); Sp 89.3% (95% CI 71.8-97.7)] (Figure 4).
In order to increase the sensitivity of the test two
thromboelastometric parameters (in-TEMW MCE and fib-
TEMW MCE) were used as two parallel tests; subse-
quently, the sensitivity rose to a point value of 99% (95%
CI 85.4-99.9). In this way, the two variables might be used
together as a unique test.
Calculation of the sample size useful to exclude the
presence of any treatment in a herd size of a finite popu-
lation showed that: 1) in the first situation, taking into
account each MCE parameter one at time and setting aFigure 2 Box-plots representing the significant difference in in-TEMW
corticosteroids and the control ones (P < 0.05).95% confidence level, a design prevalence of 33% (equal
to the prevalence of treated of this study), and the level
of sensitivity given by the low band of the CI (i.e. 57.2%)
the sample size would be 16 heads when using the in-
TEM MCE; and 14 heads when using the low band of
the CI of the fib-TEMW MCE (i.e. 66.1%) 2) under the
same assumptions and with the low band sensitivity
obtained in the parallel tests (Se = 85.4%), the sample
size was 11 heads.
CBC revealed a hypochromic microcytic anemia in both
groups. All subjects presented hemoglobin levels >4.5 mmol
per L, as required by European regulations (Directive
97/2/EC and Italian Decree Law 331/98) that determine
the minimum standards for the protection of calves.
Discussion
In veterinary medicine, TEM/TEG has been used to inves-
tigate different conditions of hypocoagulabilty [25,30], andand fib-TEMW MCE values between the animals treated with
Figure 3 ROC curve of the fib-TEMW maximum clot elasticity
(MCE). MCE parameter shows a good accuracy in discriminating
treated and controls.
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in other species [20,24]. In bovine medicine, only one pre-
liminary study on thromboelastometry [32] has been pub-
lished to date. In this study the analytical performance of
the instrument in the bovine species has been evaluated
and coefficients of variation have been calculated. In gen-
eral, in cattle, as in dogs [33], the use of strong clotting ac-
tivators (as the in-TEMW and ex-TEMW reagents), instead
of recalcification only (as in na-TEMW) reduce the impact
of pre-analytical phactors on TEM tracings and allow
more reproducible results. Furthermore it is not known at
this moment if also in cattle, as in human beings, the
TEM results are influenced by age and gender (Sucker
et al. 2011). For this reason further studies are necessary
to investigate the impact of age, gender and also breed cat-
egory (e.g. dairy vs. beef breed) on TEM results.
The results of the present study indicate a hyperco-
agulable condition in the dexamethasone-treated groupFigure 4 ROC curve of the in-TEMW maximum clot elasticity
(MCE). MCE parameter shows a good accuracy in discriminating
treated and controls.(increase in alpha angle and MCF with a reduction in
CFT on all profiles; decrease in CT on the in-TEMW
profile), with the involvement of both plasma and cellu-
lar components of hemostasis. Interestingly, the CT was
shortened on the in-TEMW profile of the treated calves
but prolonged on the ex-TEMW and fib-TEMW profiles.
This difference could be explained by an increase in the
activity of factor VIII and XI, as observed in humans
after corticosteroid administration [10]. Both factors are
involved in the intrinsic pathway (in-TEMW), whereas
the profiles triggered by tissue factor (ex-TEMW and fib-
TEMW) are less influenced by these changes. The reason
for CT prolongation in the ex-TEMW and fib-TEMW
profiles is not clear. Further qualitative assessments of
the hemostatic process (e.g., plasma factor levels) are
needed to elucidate these changes.
In human studies, hypercoagulability after corticoster-
oid administration has been related also to an increase
in fibrinogen levels [10]. This condition could be the
cause for the increase in the MCF observed in this study.
A significant increase in MCF was observed not only on
the in-TEMW and ex-TEMW profiles but also on the fib-
TEMW profile, where platelet contribution to clot stabil-
ity is annulled by the addition of cytochalasin D. Here,
again, further studies are needed to quantify the contri-
bution of factor XIII. A limitation of this study is the
lack of fibrinogen concentration measurement.
Certain preanalytical factors are known to influence the
thromboelastometric results in different species (e.g., sam-
pling technique and storage condition) [24,33]. Also,
because TEG tracings can be altered in some pathologic
conditions due to an increase or a decrease hemostasis
[21,23,34,35], it is essential to standardize sampling tech-
nique and storage conditions and to evaluate the patient’s
clinical status when performing TEM analysis, as was
done in the present study.
The results of the ROC curves show that parameters
such as in-TEM MCE and fib-TEM MCE are able to
identify cattle treated with dexamethasone for long pe-
riods at low doses. These preliminary results could be
useful in field identification of illicitly treated cattle, even
in a fairly small (n = 11) sample of heads simultaneously
treated in each herd.
All the calves in both groups were affected by anemia
due to the particular zootechnic. This variation in
hematocrit is known to affect the TEM tracing, also in
bovine species, since it increases the blood coagulability
measured by the instrument [32]. It is not known
whether this phenomenon reflects an in vivo effect of
red blood cell mass on hemostasis or whether it is sim-
ply an artifact of the viscoelastic technology [27]. In our
study, anemia was not considered as a confounding fac-
tor, because both groups showed the same severity of
anemia. It is not known, at this moment, if the anemia
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the hemostatic changes secondary to dexamethasone
treatment. For this reason, further studies are necessary
to investigate the effects of dexamethasone in bovines
not affected by anemia.
To the best of authors’ knowledge this is the first study
to assess the effect of steroids on blood coagulation in
bovines.Conclusions
The results of this preliminary study suggest that TEM
may be useful in the detection of illicit low-dose dexa-
methasone treatment. Further studies on larger popula-
tions are needed to improve the accuracy of results.
While TEM holds promise as a tool for use in the field,
other relevant data are necessary in order to apply
thrombolestometry in the detection of illicit drug treat-
ment: the method’s analytical sensibility threshold in re-
lation to various dosages, the treatment duration, and
the length of time following treatment during which al-
tered hemostasis can still be reliably detected.Endnotes
aCommission Regulation (EC) No 508/1999 of 4 March
1999 amending Annexes I to IV to Council Regulation
(EEC) No 2377/90 laying down a Community procedure
for the establishment of maximum residue limits of veter-
inary medicinal products in foodstuffs of animal origin.
Official Journal of the European Community, L60, 16–52.
bhttp://epitools.ausvet.com.au.
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